Naurex Inc. has initiated a Phase 2 clinical trial of its lead compound GLYX-13.
GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), is being developed as a therapy for patients who are not achieving an adequate response to their current antidepressant agents. Screening and enrollment of subjects in the Phase II study are currently underway.
Naurex’s novel GFPA class of compounds has demonstrated the potential to achieve the well-documented efficacy of classic NMDAR-modulating drugs while avoiding their serious side effects. Known NMDAR-modulating agents such as ketamine have been shown to act very rapidly—within hours of a single dose—to alleviate the symptoms of depression and bipolar disorder in a number of human clinical trials, but their clinical utility has been hampered by their potential for abuse and behavioral impairment, including schizophrenia-like effects at doses near the therapeutic dose.
The GLYX-13 Phase 2 trial is a randomized, double-blind, placebo-controlled study of the efficacy and safety of GLYX-13 in treatment-resistant depression. The trial is intended to enroll 80 subjects with major depressive disorder who have demonstrated inadequate or partial response to other antidepressants. Outcome measures include ratings of signs, symptoms, and changes in depression scores on standard rating scales for mood and psychiatric disorders.
“GLYX-13 is the first in a new class of antidepressants designed to achieve the rapid onset and breakthrough efficacy of classic NMDAR modulators, but without their prohibitive side effects,” says Ronald Burch, MD, PhD, chief medical officer at Naurex.
In preclinical studies, GLYX-13 has demonstrated the antidepressant-like activity of ketamine, including its rapid onset and long duration of effect, with no signs of side effects. It also achieved the widest therapeutic ratio between efficacy and side effects of any known NMDAR modulator.
In a Phase 1 trial, GLYX-13 was well tolerated, with adverse events for the groups receiving GLYX-13 and placebo all rated as mild. There were no signs of the schizophrenia-like side effects associated with other drugs that modulate the NMDAR.
Release Date: June 22, 2011
Source: Naurex Inc.
Filed Under: Drug Discovery